REVA Medical Demonstrated Bioresorbable Scaffold
The company performed a live revascularization procedure and presented trial results during the VIVA26 conference.
Updated on Oct. 6, 2026 in Stroke
Live Poll
Do you believe new medical device technologies significantly improve health outcomes for patients?
REVA Medical showcased its investigational MOTIV bioresorbable scaffold through a live-streamed revascularization demonstration at the VIVA26 conference. The event coincided with the presentation of clinical trial results for the new device.
Why it matters
The trial data provides insight into the potential efficacy of the MOTIV scaffold compared to traditional balloon angioplasty for treating patients with complex vascular conditions.
The clinical trial enrolled 292 patients, with 69 percent of participants classified as Rutherford 5. The live demonstration utilized two MOTIV scaffolds measuring 4.0 mm by 48 mm and 3.5 mm by 24 mm.
The players
REVA Medical
This medical device company focuses on the development of bioresorbable scaffolds for vascular interventions.
Andrej Schmidt
He is a medical professional who performed the live-streamed revascularization procedure at University Hospital Leipzig.
The details
Andrej Schmidt performed the revascularization procedure at University Hospital Leipzig for remote transmission to the VIVA26 conference in Las Vegas. The demonstration involved a 72-year-old woman suffering from chronic limb-threatening ischemia.
Timeline
October 6, 2026: REVA Medical presented trial results and conducted a live procedure at the VIVA26 conference.
Health Landscape
This demonstration fits into the broader trajectory of the VIVA conference vascular intervention research program, which serves as a global platform for vetting new device data. The presentation marks a significant milestone in evaluating bioresorbable scaffolds against conventional angioplasty standards.
The trial findings highlight potential future treatment alternatives for patients dealing with chronic limb-threatening ischemia. As the device remains investigational, patients should consult with vascular specialists regarding currently approved therapies and their individual health needs.
The takeaway
The use of bioresorbable scaffolds represents an evolving approach to managing complex arterial blockages without permanent implants. Patients with ischemia should continue to work closely with their medical teams to understand the latest options emerging from these ongoing clinical trials.
Further reading
Learn more about the latest innovations in vascular health at our Stroke section.
Live Poll
Do you believe new medical device technologies significantly improve health outcomes for patients?
